医学
类风湿性关节炎
抗风湿药物
Janus激酶抑制剂
耐火材料(行星科学)
抗风湿药
贾纳斯激酶
内科学
关节炎
托法替尼
受体
物理
天体生物学
作者
Mark C. Genovese,Joel Kremer,Omid Zamani,Charles Ludivico,Marek Krogulec,Lechun Xie,Scott Beattie,Alisa E. Koch,Tracy Cardillo,Terence Rooney,William L. Macias,Stephanie de Bono,D. Schlichting,Josef S. Smolen
标识
DOI:10.1056/nejmoa1507247
摘要
In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biologic disease-modifying antirheumatic drugs (DMARDs).
科研通智能强力驱动
Strongly Powered by AbleSci AI